Impact of Lipid-Lowering Therapy on Outcomes in Atrial Fibrillation

American Journal of Cardiology

Volumn 105, Issue 12, 2010, Pages 1768-1772

  Badheka, Apurva O ^a   Rathod, Ankit ^a   Kizilbash, Mohammad A ^a   Garg, Neha ^a   Mohamad, Tamam ^a   Afonso, Luis ^a   Jacob, Sony ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; EMBOLISM; FEMALE; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; STROKE;

AGED; ANTILIPEMIC AGENTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77953122374     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.358     Document Type: Article

References (29)

1. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., and Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 52 (2008) 1769-1781
2. O'Regan C., Wu P., Arora P., Perri D., and Mills E.J. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 121 (2008) 24-33
3. Hulten E., Jackson J.L., Douglas K., George S., and Villines T.C. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 1814-1821
4. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., and Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
5. Afilalo J., Duque G., Steele R., Jukema J.W., de Craen A.J., and Eisenberg M.J. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 51 (2008) 37-45
6. Atrial Fibrillation Follow-up Investigation of Rhythm Management-the AFFIRM study design. The planning and steering committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol 79 (1997) 1198-1202
7. AFFIRM Investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. Am Heart J 143 (2002) 991-1001
8. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., and Corley S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
9. Corley S.D., Epstein A.E., DiMarco J.P., Domanski M.J., Geller N., Greene H.L., Josephson R.A., Kellen J.C., Klein R.C., Krahn A.D., Mickel M., Mitchell L.B., Nelson J.D., Rosenberg Y., Schron E., Shemanski L., Waldo A.L., and Wyse D.G. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 (2004) 1509-1513
10. Sherman D.G., Kim S.G., Boop B.S., Corley S.D., Dimarco J.P., Hart R.G., Haywood L.J., Hoyte K., Kaufman E.S., Kim M.H., Nasco E., and Waldo A.L. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 165 (2005) 1185-1591
11. Camm J. Atrial fibrillation-an end to the epidemic?. Circulation 112 (2005) iii
12. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
13. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
14. Boos C.J., Anderson R.A., and Lip G.Y. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27 (2006) 136-149
15. Savelieva I., and Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 5 (2008) 30-41
16. Adam O., Neuberger H.R., Bohm M., and Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 118 (2008) 1285-1293
17. Di Napoli P., Taccardi A.A., Grilli A., De Lutiis M.A., Barsotti A., Felaco M., and De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66 (2005) 462-471
18. Landmesser U., Engberding N., Bahlmann F.H., Schaefer A., Wiencke A., Heineke A., Spiekermann S., Hilfiker-Kleiner D., Templin C., Kotlarz D., Mueller M., Fuchs M., Hornig B., Haller H., and Drexler H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
19. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., Hausmann D., Beckmann S., and Gross M. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
20. Coleman C.I., Kluger J., Bhavnani S., Clyne C., Yarlagadda R., Guertin D., and White C.M. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. Heart Rhythm 5 (2008) 507-510
21. Bhavnani S.P., Coleman C.I., White C.M., Clyne C.A., Yarlagadda R., Guertin D., and Kluger J. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace 10 (2008) 854-859
22. Hylek E.M., Frison L., Henault L.E., and Cupples A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 39 (2008) 3009-3014
23. Chello M., Spadaccio C., Patti G., Lusini M., Barbato R., Goffredo C., Di Sciascio G., and Covino E. Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis 197 (2008) 588-595
24. Choudhury A., Chung I., Panja N., Patel J., and Lip G.Y. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest 134 (2008) 574-581
25. Ferro D., Loffredo L., Polimeni L., Fimognari F., Villari P., Pignatelli P., Fuster V., and Violi F. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 27 (2007) 2763-2768
26. Lip G.Y., Patel J.V., Hughes E., and Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 38 (2007) 1229-1237
27. Hanna I.R., Heeke B., Bush H., Brosius L., King-Hageman D., Dudley Jr. S.C., Beshai J.F., and Langberg J.J. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3 (2006) 881-886
28. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., and Hallstrom A.P. Are lipid-lowering drugs also antiarrhythmic drugs?. An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
29. McLean D.S., Ravid S., Blazing M., Gersh B., Shui A., and Cannon C.P. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J 155 (2008) 298-302